Compare Neurocrine Biosciences Inc (NBIX) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Omnicom Group Inc. — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Omnicom Group Inc. trades at $79.22 (market cap $23.48B). The key difference: Omnicom Group Inc. is the larger of the two by market cap, and Omnicom Group Inc. pays a 3.88% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | OMC | |
|---|---|---|
Market Cap | $17.40B | $23.48B |
Sector | Health | Media |
52-Week High | $180.55 | $85.80 |
52-Week Low | $123.10 | $67.27 |
Enterprise Value | $16.49B | $30.70B |
Dividend Yield | — | 3.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Omnicom Group (OMC) trades at $79.21, down 3.08% today, with a bullish technical signal from moving averages. The company reported mixed Q1 2026 earnings, beating expectations with $1.90 EPS versus $1.82 expected, but Q4 2025 missed at $2.59 versus $2.72. Revenue growth is strong, reaching $17.27 billion in 2025, though net income was negative $54.50 million due to elevated taxes. Analyst consensus is mixed with 32% buy ratings and a $105.75 price target, representing significant upside. Recent news highlights major client wins including IBM's global media account and partnerships with Netflix and Disney.
OMC presents a value opportunity with a low P/E of 12.16 and P/S of 0.96, trading below analyst targets. The advertising holding company benefits from AI platform expansion and strategic partnerships, but faces margin pressure and intense competition. Near-term catalysts include Q2 2026 earnings on July 28, 2026, where the company must deliver on the expected $2.58 EPS to maintain investor confidence amid current bearish sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
